市場調查報告書
商品編碼
1491661
心臟輔助設備市場:按類型、模式和最終用戶分類 - 全球預測 2024-2030Cardiac Assist Devices Market by Type (Extracorporeal Membrane Oxygenation, Intra-Aortic Balloon Pump (IABP), Total Artificial Hearts (TAH)), Modality (Implantable, Transcutaneous), End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年心臟輔助設備市場規模為14.6億美元,預計2024年將達15.5億美元,2030年將達到22.8億美元,複合年成長率為6.51%。
心臟輔助設備 (CAD) 是先進的醫療設備,旨在支援和增強心臟衰竭和其他心臟相關疾病患者的心臟泵血功能。 CAD 在末期心臟衰竭患者的管理、與心臟移植、目的地治療以及術中和術後心臟支持的聯繫中發揮著重要作用。由於久坐的生活方式、人口老化以及高血壓和糖尿病盛行率的增加,全世界心血管疾病的盛行率不斷增加,這增加了對心臟輔助設備的需求。此外,全球對先進心臟支持方案的認知不斷提高,以及新興國家不斷上漲的醫療成本也促進了市場成長。此外,與設備植入相關的風險和併發症,例如感染疾病、出血和設備故障,對心臟輔助設備市場的成長構成了重大挑戰。此外,提高心臟輔助設備有效性和安全性的技術進步,導致醫療保健提供者和患者更廣泛接受,預計將為市場創造成長機會。
主要市場統計 | |
---|---|
基準年[2023] | 14.6億美元 |
預測年份 [2024] | 15.5億美元 |
預測年份 [2030] | 22.8億美元 |
複合年成長率(%) | 6.51% |
區域洞察
由於心血管疾病的高發生率、強大的醫療基礎設施以及大量的研發投資,美洲是一個市場格局高度發展的地區。該地區受益於專注於創新並推出技術先進產品的主要市場參與者的存在。美國醫療設備法規和政策也促進了新技術的快速採用。此外,人口老化的加劇和有利的報銷方案進一步刺激了市場成長。亞太地區心臟輔助設備市場正在成長,這主要是由於心臟疾病率上升、醫療基礎設施改善以及醫療費用上漲。中國、印度等國家人口眾多,中等收入階層不斷壯大,為市場拓展提供了巨大機會。該地區也受益於政府旨在改善醫療保健機會的措施。由於先進的醫療保健系統、高昂的醫療成本和心血管疾病的盛行率增加,EMEA(歐洲、中東和非洲)地區的心臟輔助設備前景廣闊。德國、英國和法國等國家在有利的醫療政策、高水準的意識層級和完善的醫療基礎設施的推動下處於領先地位。由於醫療保健投資的增加和對醫療保健現代化的興趣日益濃厚,中東地區正在快速成長。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在心臟輔助設備市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對心臟輔助設備市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在心臟輔助設備市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[187 Pages Report] The Cardiac Assist Devices Market size was estimated at USD 1.46 billion in 2023 and expected to reach USD 1.55 billion in 2024, at a CAGR 6.51% to reach USD 2.28 billion by 2030.
Cardiac assist devices (CADs) are sophisticated medical devices designed to support and augment the pumping function of the heart in patients with heart failure or other heart-related conditions. They play a critical role in managing end-stage heart failure patients, providing a bridge to heart transplantation, serving as a destination therapy, or supporting the heart during or after surgeries. The increase in the prevalence of cardiovascular diseases worldwide, attributable to sedentary lifestyles, aging populations, and the rise in hypertension and diabetes, has surged the need for cardiac assist devices. Additionally, the expanding global awareness about the available advanced cardiac support options and the growing healthcare expenditures in emerging economies are also contributing to the market growth. Moreover, the risks and complications associated with device implantation, such as infections, bleeding, and device malfunction, pose significant challenges to the growth of the cardiac assist devices market. Furthermore, technological advancements that improve the efficacy and safety of cardiac assist devices that broaden their acceptance among healthcare providers and patients are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.46 billion |
Estimated Year [2024] | USD 1.55 billion |
Forecast Year [2030] | USD 2.28 billion |
CAGR (%) | 6.51% |
Regional Insights
The Americas represents a highly developing landscape for the global market for cardiac assist devices due to the high prevalence of cardiovascular diseases, robust healthcare infrastructure, and significant investments in research and development. The region benefits from the presence of key market players that focus on innovation and launching technologically advanced products. Medical device regulation policies in the US are also conducive to the rapid adoption of new technologies. Moreover, the increasing aging population and favorable reimbursement scenarios further stimulate market growth. The APAC region is witnessing growth in the cardiac assist devices market, attributed mainly to the rising incidence of cardiac diseases, improving healthcare infrastructure, and increasing healthcare expenditure. Countries including China and India, with their vast population bases and growing middle-class, present significant opportunities for market expansion. The region also benefits from government initiatives aimed at improving healthcare access. The EMEA region showcases a strong landscape for cardiac assist devices due to its advanced healthcare system, high healthcare expenditure, and increasing prevalence of cardiovascular diseases. Countries such as Germany, the UK, and France are at the forefront, driven by favorable healthcare policies, high awareness levels, and well-established healthcare infrastructure. The Middle East is rapidly growing due to increasing healthcare investments and a growing focus on healthcare modernization.
Market Insights
The market dynamics represent an ever-changing landscape of the Cardiac Assist Devices Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Assist Devices Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Assist Devices Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Supira Medical's Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference
Supira Medical, Inc. launched a percutaneous ventricular assist device (pVAD), including an anticipated live case demonstration. This inclusion underscores the system's pioneering approach, characterized by its minimal invasiveness and superior continuous flow capabilities, which are poised to revolutionize hemodynamic support for both practitioners and patients alike. [Published On: 2023-10-20]
Abbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker
Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its groundbreaking AVEIR DR leadless pacemaker system, marking a significant milestone in cardiac care technology. This innovative system, which is the first of its kind to offer dual chamber leadless pacing, is designed to address the needs of patients experiencing abnormal or slow heart rhythms by providing pacing to both the right atrium and right ventricle. This approval is poised to benefit millions of Americans, as over 80% of pacemaker users require dual-chamber pacing. The AVEIR DR system represents a leap forward in medical technology, providing an expanded range of leadless pacing options and enhancing the treatment capabilities for individuals with heart rhythm disorders. [Published On: 2023-07-05]
UltraLinQ to Launch New Cardiac Monitoring Product at Arab Health
Ultralinq announced the launch of ITS latest product in cardiac monitoring at Arab Health. This innovative solution offers advanced and comprehensive Holter ECG monitoring for improved patient care. The state-of-the-art Holter ECG monitor can record and store up to 14 days of high-quality ECG data. Its user-friendly design simplifies the patient experience and reduces the time spent during clinic appointments. [Published On: 2023-01-31]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Assist Devices Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Assist Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AlivCor Inc., Bardy Diagnostics, Inc., Berlin Heart GmbH, BiVACOR Inc., Boston Scientific Corporation, Cardiac Insight, Inc., Cardiobridge GmbH, CorInnova, Inc., CorWave SA, GE HealthCare Technologies Inc., Getinge AB, Hill-Rom Holdings, Inc., Jarvik Heart Inc., Koninklijke Philips N.V., LivaNova PLC, Medtronic PLC, OSI Systems, Inc., Supira Medical, Teleflex Incorporated, Terumo Corporation, and Xenios AG.
Market Segmentation & Coverage